What is ALT's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.51B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ALT?

P/E (TTM) is n/a and 52-week range is $2.55 to $6.44 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ALT figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ALT?

The company profile lists revenue (TTM) near $39K, net income (TTM) near $-8.36B, EPS (TTM) near $-0.78 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Altimmune Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Gaithersburg, Maryland, US, 194.5M shares outstanding, ISIN US02155H2004 when available from company profile and filing metadata.

Altimmune Inc

$ALT

Health Care · Biotechnology

IR Run Scenarios

$2.61

+0.38%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 57 full-time employees. The company went IPO on 2005-10-06. The firm is developing novel therapies for serious liver diseases. Its lead product candidate, pemvidutide (formerly ALT-801), is a balanced 1:1 glucagon/GLP-1 dual receptor agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, whereas the activation of GLP-1 receptors mediates suppression of appetite and reduction of cravings as well as metabolic effects such as weight loss. The company has completed phase II development of pemvidutide. The company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.

Employees

Website

altimmune.com/

IPO

2005-10-06

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)